CN1500505A - 一种治疗小儿病毒性肺炎的药物组合物及其制备方法 - Google Patents
一种治疗小儿病毒性肺炎的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN1500505A CN1500505A CNA021381755A CN02138175A CN1500505A CN 1500505 A CN1500505 A CN 1500505A CN A021381755 A CNA021381755 A CN A021381755A CN 02138175 A CN02138175 A CN 02138175A CN 1500505 A CN1500505 A CN 1500505A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- semen
- present
- radix
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 title claims abstract description 9
- 206010035664 Pneumonia Diseases 0.000 title abstract description 7
- 241000700605 Viruses Species 0.000 title abstract description 5
- 229940079593 drug Drugs 0.000 title description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 32
- 210000000582 semen Anatomy 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 9
- 241000255791 Bombyx Species 0.000 claims description 8
- 206010035737 Pneumonia viral Diseases 0.000 claims description 8
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 8
- 208000009421 viral pneumonia Diseases 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000007901 soft capsule Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 1
- 206010011224 Cough Diseases 0.000 abstract description 11
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 208000026435 phlegm Diseases 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 244000144725 Amygdalus communis Species 0.000 abstract 1
- 235000011437 Amygdalus communis Nutrition 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 241000218671 Ephedra Species 0.000 abstract 1
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 235000008040 Peucedanum palustre Nutrition 0.000 abstract 1
- 240000007078 Peucedanum palustre Species 0.000 abstract 1
- 235000020224 almond Nutrition 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 229910052602 gypsum Inorganic materials 0.000 abstract 1
- 239000010440 gypsum Substances 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 18
- 239000000341 volatile oil Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 6
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000008570 maxingshigan Substances 0.000 description 4
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 description 3
- 230000000954 anitussive effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- -1 hydroxypropyl Chemical group 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 206010037833 rales Diseases 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229940101006 anhydrous sodium sulfite Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000027685 extreme exhaustion Diseases 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种中药复方制剂,特别是一种治疗小儿病毒性肺炎的药物组合物及其制备方法。本发明的药物组合物由麻黄、苦杏仁、石膏、甘草、前胡、僵蚕、丹参、虎杖、拳参、葶苈子、桑白皮十一味中药组成。本发明药物组合物具有显著的抗病毒、抗菌、解热抗炎、镇咳祛痰作用,对小儿病毒性肺炎有很好的治疗效果,且无不良反应。
Description
本发明涉及一种中药复方制剂,特别是指一种治疗小儿病毒性肺炎的药物组合物及其制备方法。
临床病毒性肺炎以小儿为多见,是儿科临床的常见病与多发病。患者一般有发热、咳嗽、气喘,肺部有罗音;重者出现持续高热不退、心悸气急、紫疳、极度衰竭、休克等危象。目前西医尚无有效的抗病毒性肺炎药物,化学药物中抗菌素、抗病毒药对病毒性肺炎疗效不可靠,疗程长、病情易反复。而中医根据其病理特征配伍用药,常取得显著疗效。
本发明药物组合物处方源于汉代张仲景名方《麻杏石甘汤》,据多年临床经验加味而成。麻杏石甘汤宣泄肺热、止咳平喘,当代常用于治疗肺炎、慢性支气管炎、支气管哮喘,麻疹,百日咳等症。目前报道的以麻杏石甘汤为基础可用于治疗小儿病毒性肺炎的中成药有:儿童清肺口服液、小儿清肺化痰口服液、小儿麻甘冲剂(国家非处方药药品目录),陕西汉中市中医院的麻虎合剂<陕西中医2001,(5)>,此外还有“治疗小儿肺炎药物的生产方法”(中国专利CN92109826)等,但未检索到与本发明药物组合物处方相同的药物。
本发明药物组合物在麻杏石甘汤的基础上增加了七味中药,组方独特。方中前胡宣开肺气、降气化痰,僵蚕疏散风邪、燥湿化痰,丹参、虎杖、拳参三药同用对肺热炽盛,壅血为瘀的肺部炎症具有一定的消散作用,甘草用于调和诸药,特别对防止麻黄辛散太过导致的心律加快,石膏的寒凉引起的胃脘痛等不良反应可起的一定的预防作用。全方具有宣束肺气,清化痰热,解毒活血的功效,主治小儿病毒性肺炎临床疗效显著,特别对发热不退,咳嗽反复不止,肺部湿罗音不消等有很好的治疗效果。
本发明的目的在于提供一种对小儿病毒性肺炎有良好的治疗作用、无不良反应的药物组合物及其制备方法。
本发明的目的是通过如下措施实现的:
本发明药物组合物的组成为:麻黄、苦杏仁、石膏、甘草、前胡、僵蚕、丹参、虎杖、拳参、葶苈子、桑白皮。
将上述十一味药用水、有机溶剂或含水有机溶剂采用适当的方法提取,经浓缩或干燥或与药学上可接受的各种附加剂混合,制成本发明的药物组合物。
本发明的药物组合物的提取方法可以是:先将本发明药物配方中含有挥发油的药材如麻黄、苦杏仁提取挥发油;再将提挥发油剩余药渣和芳香水与其余药材石膏、葶苈子、桑白皮、前胡、僵蚕、丹参、虎杖、拳参、甘草用水、有机溶剂或含水有机溶剂提取;也可以不提取挥发油,将本发明药物组合物的十一味药:麻黄、苦杏仁、石膏、甘草、前胡、僵蚕、丹参、虎杖、拳参、葶苈子、桑白皮直接用水、有机溶剂或含水有机溶剂提取。有机溶剂可以是乙醇、甲醇、丙醇等醇类或丙酮,也可以是二氯甲烷、氯仿等卤代烷类或乙酸乙酯、乙酸丁酯等酯类。
本发明的药物组合物可以含有药学上可接受的各种附加剂,这些附加剂包括填充剂、稀释剂、包结剂、溶剂、矫味剂、防腐剂、助溶剂、稳定剂、pH调节剂、分散剂、崩解剂、润滑剂、乳化剂、粘合剂、表面活性剂和色素等,或它们的混合物。
本发明的药物组合物的剂型可以是颗粒剂、糖浆剂、胶囊剂、片剂、口服液、软胶囊、丸剂、乳剂、喷剂、滴剂、栓剂、注射剂。
药学上可接受的附加剂具体可以是糊精、蔗糖、淀粉、环糊精、微晶纤维素、羧甲基纤维素、羧甲基淀粉、羟丙基甲基纤维素、羟丙基纤维素、乙基纤维素、水、乙醇、丙二醇、甘油、聚乙二醇、聚维酮、植物油、硬脂酸镁、滑石粉、山梨醇、尼泊金、吐温等,但不限于以上品种。
本发明的药物组合物经生物活性试验,显示有良好的抗病毒、抗菌、解热抗炎、镇咳祛痰作用,未测出毒性,具体见以下试验例。
试验例1:体内抗病毒试验
小鼠每组10只,分别灌胃给予本发明药物组合物小、中、大剂量、及对照,给药3小时后小鼠鼻腔内接种流感病毒液,以后每天给药2次,共5天。计算小鼠15天内的平均生活天数及延长生命率。结果见下表:
动物数 平均生活 延长生
组别
(只) 天数(天) 命率(%)
对照 10 4.2
小剂量组 10 6.5* 54.8
中剂量组 10 6.8* 61.9
大剂量组 10 7.9** 88.1
与对照组比较,*P<0.05,**P<0.01。
结果表明,本发明药物组合物各剂量组可使流感病毒感染小鼠平均生存天数延长,延长生命率最大可延长88.1%,说明其具有显著的抗病毒作用。
试验例2:体内抗肺炎链球菌试验
小鼠每组15只,腹腔注射肺炎链球菌培养液0.1ml/只,感染后立即分别灌胃给予本发明药物组合物小、中、大剂量及对照,每日3次,给药3天。观察7天内小鼠的死亡数。结果见下表:
组别 动物数(只) 死亡数(只) 死亡率(%)
对照组 15 15 100.0
小剂量组 15 13 86.7
中剂量组 15 9 60.0*
大剂量组 15 8 53.3**
与对照组比较,*P<0.05,**P<0.01。
结果表明,本发明药物组合物中、大剂量组均能降低肺炎链球菌感染小鼠死亡率,对肺炎链球菌感染的小鼠有明显保护作用。
试验例3:解热试验
大鼠每组10只,于右足跖皮下注射1%角叉菜胶0.1ml/只,给药后立即分别灌胃给予本发明药物组合物小、中、大剂量和对照,注射后0.5、1、2、3小时测量大鼠肛温。计算大鼠肛温升高值,结果见附图:
上述试验结果显示,本发明药物组合物各剂量组对角叉菜胶所致大鼠发热反应均有一定的抑制作用,给药1小时即可起效,抑制率为51%,说明其具有一定的解热作用。
试验例4:镇咳试验
小鼠每组10只,分别灌胃给予本发明药物组合物小、中、大剂量及对照,给药1小时后,将小鼠迅速放入倒置的内盛无水亚硫酸钠0.35g和50%硫酸5ml的1000ml烧杯中,观察小鼠咳嗽潜伏期和2分钟内咳嗽次数。结果见下表:
组别 咳嗽潜伏时间(S) 咳嗽次数(次)
对照组 48.8±9.5 50.2±15.5
大剂量组 58.4±8.4* 36.7±12.3*
中剂量组 57.8±9.4* 36.0±10.7*
小剂量组 47.710.6 49.0±13.7
注:与对照组比较,*P<0.05。
试验结果显示,本发明药物组合物大、中剂量组对SO2所致小鼠咳嗽反应均有一定的抑制作用,可使咳嗽潜伏时间显著延长,咳嗽次数显著减少,表明其具有良好的镇咳作用。
试验例5:祛痰试验
小鼠每组10只,分别灌胃给予本发明药物组合物小、中、大剂量及对照,给药1小时后,腹腔注射5%酚红溶液0.1ml/10g,30分钟后处死小鼠,冲洗气管,测定洗涤液光密度值,在酚红标准曲线上查出相应的酚红浓度。结果见下表:
组别 酚红排出量(μg/ml) 增长百分率(%)
对照组 0.54±0.21
小剂量组 0.75±0.23* 38.9
中剂量组 0.82±0.30* 51.9
大剂量组 0.91±0.27** 68.5
与对照组比较,*P<0.01,**P<0.01。
结果表明,本发明药物组合物各剂量组均能明显促进小鼠气管酚红排出,最大增长率可达68.5%,说明其具有较好的祛痰作用。
试验例6:抗炎试验
小鼠每组10只,分别灌胃给予本发明药物组合物小、中、大剂量及对照。每天给药3次,连续2天,末次给药后1小时,用二甲苯0.02ml/只均匀涂抹于小鼠左耳前后两面,右耳作为对照。1小时后将小鼠处死,用9mm打孔器在两耳同一部位打下耳片并称重,以两耳重量之差为耳廓肿胀度。结果见下表:
耳廓肿胀度 耳廓肿胀率 抑制率
组别
(mg) (%) (%)
对照组 10.8±1.7 164.6±33.4
小剂量组 9.7±2.6 140.0±42.1 14.9
中剂量组 9.0±2.0* 134.5±39.4* 18.3
大剂量组 8.8±2.2* 128.8±42.2* 21.7
与对照组比较,*P<0.05。
结果表明,本发明药物组合物中、大剂量组均可显著抑制二甲苯所致的小鼠耳廓炎症,抑制率最大可为21.7%,说明其具有一定的抗炎作用。
试验例7:毒性试验
本发明药物组合物小鼠经口给药未能测出LD50,经口给药的最大耐受量试验表明,20只小鼠按735g生药/Kg/日给药后均无异常情况发生,1周内亦无死亡。该剂量为临床人日口服剂量的58.4倍。
以下通过实施例对本发明作进一步的详细阐述:
实施例1
称取麻黄150g、苦杏仁320g、石膏600g、甘草350g、前胡250g、僵蚕200g、丹参300g、虎杖350g、拳参400g、葶苈子240g、桑白皮400g,将麻黄和苦杏仁蒸馏提取出挥发油;石膏粉碎加水先煎10分钟,再将提取挥发油剩余的药渣和芳香水及甘草、前胡、僵蚕、丹参、虎杖、拳参、葶苈子、桑白皮加入,合并煎煮两次,每次半小时,煎液合并过滤。滤液减压浓缩至相对密度为1.20(90℃热测)的浸膏液,放冷至室温,加乙醇调节至含醇量70%(w/w),静置15小时。取上清液,减压浓缩至相对密度为1.31(90℃热测)的浸膏,合并挥发油和浸膏,加入口服液常用的赋形剂,采用口服液常规制备工艺,制成口服液。
实施例2
按照实施例1的方法挥发油和浸膏,加入颗粒剂常用的赋形剂,采用颗粒剂常规制备工艺,制成颗粒剂。
实施例3
按照实施例1的方法提取挥发油和浸膏,经喷雾干燥制成颗粒剂。
实施例4
按照实施例1的方法提取挥发油和浸膏,加入糖浆剂常用的赋形剂,采用糖浆剂常规制备工艺,制成糖浆剂。
实施例5
按照实施例1的方法提取挥发油和浸膏,经喷雾干燥制成干燥颗粒,装入空心胶囊,制成胶囊剂。
实施例6
按照实施例1的方法提取挥发油和浸膏,加入片剂常用的赋形剂,采用片剂常规制备工艺,制成片剂。
实施例7
按照实施例1的方法提取挥发油和浸膏,浓缩后采用软胶囊的常规制备工艺,制成软胶囊。
实施例8
按照实施例1的方法提取挥发油和浸膏,加入喷雾剂常用的赋形剂,采用喷雾剂常规制备工艺,制成喷雾剂。
Claims (3)
1.一种治疗小儿病毒性肺炎的药物组合物,其特征在于:是由下列药物组成:麻黄、苦杏仁、石膏、甘草、前胡、僵蚕、丹参、虎杖、拳参、葶苈子、桑白皮。
2.根据权利要求1所述的药物组合物的制备方法,其特征在于:将本发明药物组合物的十一味药:麻黄、苦杏仁、石膏、甘草、前胡、僵蚕、丹参、虎杖、拳参、葶苈子、桑白皮用水、有机溶剂或含水有机溶剂采用适当的方法提取,经浓缩或干燥或与药学上可接受的附加剂混合,制成本发明的药物组合物。
3.根据权利要求1或2所述的药物组合物,其特征在于:药物组合物的剂型可以是颗粒剂、口服液、糖浆剂、胶囊剂、片剂、软胶囊、丸剂、乳剂、喷剂、滴剂、栓剂、注射剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02138175 CN1231242C (zh) | 2002-08-26 | 2002-08-26 | 一种治疗小儿病毒性肺炎的药物组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02138175 CN1231242C (zh) | 2002-08-26 | 2002-08-26 | 一种治疗小儿病毒性肺炎的药物组合物及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1500505A true CN1500505A (zh) | 2004-06-02 |
| CN1231242C CN1231242C (zh) | 2005-12-14 |
Family
ID=34231719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02138175 Expired - Fee Related CN1231242C (zh) | 2002-08-26 | 2002-08-26 | 一种治疗小儿病毒性肺炎的药物组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1231242C (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100435817C (zh) * | 2005-09-28 | 2008-11-26 | 大连美罗中药厂有限公司 | 一种治疗呼吸系统疾患的中药组合物及其制备方法 |
| CN102429972A (zh) * | 2010-12-23 | 2012-05-02 | 河南天方药业中药有限公司 | 一种治疗小儿病毒性支气管肺炎的口服液及其制备工艺 |
| US9687012B2 (en) | 2013-02-12 | 2017-06-27 | Uriel KESLER | Non-dairy formulae |
| CN107281333A (zh) * | 2017-08-21 | 2017-10-24 | 北京煜煌科技有限公司 | 一种儿科用口服胶囊及其制备方法 |
-
2002
- 2002-08-26 CN CN 02138175 patent/CN1231242C/zh not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100435817C (zh) * | 2005-09-28 | 2008-11-26 | 大连美罗中药厂有限公司 | 一种治疗呼吸系统疾患的中药组合物及其制备方法 |
| CN102429972A (zh) * | 2010-12-23 | 2012-05-02 | 河南天方药业中药有限公司 | 一种治疗小儿病毒性支气管肺炎的口服液及其制备工艺 |
| US9687012B2 (en) | 2013-02-12 | 2017-06-27 | Uriel KESLER | Non-dairy formulae |
| US10575546B2 (en) | 2013-02-12 | 2020-03-03 | Else Nutrition Gh Ltd | Non-dairy formulae |
| US11246332B2 (en) | 2013-02-12 | 2022-02-15 | Else Nutrition Gh Ltd | Non-dairy formulae |
| CN107281333A (zh) * | 2017-08-21 | 2017-10-24 | 北京煜煌科技有限公司 | 一种儿科用口服胶囊及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1231242C (zh) | 2005-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101700307B (zh) | 一种治疗慢性咽喉炎的中药 | |
| CN103768308B (zh) | 一种用于治疗上呼吸道感染的药物组合物及其制备方法 | |
| CN101683420B (zh) | 一种中药组合物在制备治疗急性咽炎药物中的应用 | |
| CN1927160A (zh) | 漱口液及制备方法 | |
| CN103977314A (zh) | 一种治疗呼吸道疾病的药物组合物及制备方法和用途 | |
| CN100344313C (zh) | 治疗小儿感冒及反复感冒的中成药及其制备方法 | |
| CN101564458B (zh) | 一种中药组合物在制备治疗支气管炎药物中的应用 | |
| CN104324125B (zh) | 一种治疗慢性咽炎的中药组合物及其制备方法 | |
| CN1739734A (zh) | 治疗口腔炎症的中药制剂及其制备方法 | |
| CN1733182A (zh) | 治疗外感发热的药物组合物及其制备方法 | |
| CN100337645C (zh) | 一种治疗急性咽炎的药物组合物及其制备方法 | |
| CN1231242C (zh) | 一种治疗小儿病毒性肺炎的药物组合物及其制备方法 | |
| CN1278709C (zh) | 一种治疗感冒的药物及其制备方法 | |
| CN103463217A (zh) | 一种治疗肠炎痢疾的提取物、含其制剂及其制备方法和应用 | |
| CN101991659A (zh) | 一种具有清热解毒功能的制剂及制备方法 | |
| CN100344319C (zh) | 治疗泌尿生殖系统疾病的中药组合物及其制备方法和用途 | |
| CN1289124C (zh) | 一种治疗小儿感冒的药物及其制备方法 | |
| CN1281257C (zh) | 治疗慢性气管炎和慢性支气管炎的中药组合物及其应用 | |
| CN1259938C (zh) | 一种治疗咳嗽的中药复方制剂及其制备方法 | |
| CN1943729A (zh) | 一种治疗外感发热中药组合物及其制备方法 | |
| CN102091135A (zh) | 一种含体外培育牛黄的牛黄解毒丸(片、胶囊)及其制备方法 | |
| CN1927315A (zh) | 一种主治银屑病的药物及其制备方法与应用 | |
| CN106389589A (zh) | 一种具有止咳化痰功效的药物 | |
| CN1931262A (zh) | 一种治疗感冒的中药制剂 | |
| CN1820773A (zh) | 一种治疗口腔炎症的中药组合物及其制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Nanjing Kaoyou Science &. Trade Co., Ltd. Document name: Correction notice |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Nanjing Kaoyou Science &. Trade Co., Ltd. Document name: Deemed as a notice of withdrawal |
|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Guo Ping Document name: payment instructions |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Guo Ping Document name: Notification of Termination of Patent Right |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |